AstraZeneca Builds Respiratory Drug Portfolio in $2.1B Deal


Jul 31, 2014

AstraZeneca will acquire the rights to a portfolio of inhaled drugs from Barcelona-based Almirall for $875 million up front, in a deal worth up to $2.1 billion total.

According to WSJ, this deal will give AstraZeneca a key treatment for COPD - Eklira - which it currently lacks, a new type of inhaler and a portfolio of pipeline drugs, potentially helping competition with market rivals such as GSK.

A potential deal between Pfizer and AstraZeneca was squashed in late May, reportedly because Pfizer's $117 bid for AstraZeneca undervalued the drugmaker. AstraZeneca CEO Pascal Soriot has made a number of key acquisitions in his two-year tenure in order to maximize AstraZeneca's valuation.

Read the WSJ press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments